IBDEI145 ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,19869,2)
 ;;=^59973
 ;;^UTILITY(U,$J,358.3,19870,0)
 ;;=250.00^^112^1193^7
 ;;^UTILITY(U,$J,358.3,19870,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19870,1,3,0)
 ;;=3^250.00
 ;;^UTILITY(U,$J,358.3,19870,1,4,0)
 ;;=4^DIABETES MEL W/O COMP, TYPE II
 ;;^UTILITY(U,$J,358.3,19870,2)
 ;;=^33605
 ;;^UTILITY(U,$J,358.3,19871,0)
 ;;=250.02^^112^1193^6
 ;;^UTILITY(U,$J,358.3,19871,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19871,1,3,0)
 ;;=3^250.02
 ;;^UTILITY(U,$J,358.3,19871,1,4,0)
 ;;=4^DIAB MEL W/O COMP, TYPE II UNCONT
 ;;^UTILITY(U,$J,358.3,19871,2)
 ;;=^295704
 ;;^UTILITY(U,$J,358.3,19872,0)
 ;;=272.4^^112^1193^10
 ;;^UTILITY(U,$J,358.3,19872,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19872,1,3,0)
 ;;=3^272.4
 ;;^UTILITY(U,$J,358.3,19872,1,4,0)
 ;;=4^HYPERLIPIDEMIA
 ;;^UTILITY(U,$J,358.3,19872,2)
 ;;=^87281
 ;;^UTILITY(U,$J,358.3,19873,0)
 ;;=244.9^^112^1193^11
 ;;^UTILITY(U,$J,358.3,19873,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19873,1,3,0)
 ;;=3^244.9
 ;;^UTILITY(U,$J,358.3,19873,1,4,0)
 ;;=4^HYPOTHYROIDISM
 ;;^UTILITY(U,$J,358.3,19873,2)
 ;;=^123752
 ;;^UTILITY(U,$J,358.3,19874,0)
 ;;=250.01^^112^1193^5
 ;;^UTILITY(U,$J,358.3,19874,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19874,1,3,0)
 ;;=3^250.01
 ;;^UTILITY(U,$J,358.3,19874,1,4,0)
 ;;=4^DIAB MEL W/O COMP, TYPE I
 ;;^UTILITY(U,$J,358.3,19874,2)
 ;;=^33586
 ;;^UTILITY(U,$J,358.3,19875,0)
 ;;=278.01^^112^1193^13
 ;;^UTILITY(U,$J,358.3,19875,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19875,1,3,0)
 ;;=3^278.01
 ;;^UTILITY(U,$J,358.3,19875,1,4,0)
 ;;=4^OBESITY, MORBID
 ;;^UTILITY(U,$J,358.3,19875,2)
 ;;=^84844
 ;;^UTILITY(U,$J,358.3,19876,0)
 ;;=286.59^^112^1193^8
 ;;^UTILITY(U,$J,358.3,19876,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19876,1,3,0)
 ;;=3^286.59
 ;;^UTILITY(U,$J,358.3,19876,1,4,0)
 ;;=4^HEMOR D/O DUE TO CIRC ANTICOAG
 ;;^UTILITY(U,$J,358.3,19876,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,19877,0)
 ;;=268.9^^112^1193^14
 ;;^UTILITY(U,$J,358.3,19877,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19877,1,3,0)
 ;;=3^268.9
 ;;^UTILITY(U,$J,358.3,19877,1,4,0)
 ;;=4^VITAMIN D DEFICIENCY NOS
 ;;^UTILITY(U,$J,358.3,19877,2)
 ;;=^126968
 ;;^UTILITY(U,$J,358.3,19878,0)
 ;;=790.29^^112^1193^9
 ;;^UTILITY(U,$J,358.3,19878,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19878,1,3,0)
 ;;=3^790.29
 ;;^UTILITY(U,$J,358.3,19878,1,4,0)
 ;;=4^HYPERGLYCEMIA
 ;;^UTILITY(U,$J,358.3,19878,2)
 ;;=^329955
 ;;^UTILITY(U,$J,358.3,19879,0)
 ;;=285.21^^112^1193^2
 ;;^UTILITY(U,$J,358.3,19879,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19879,1,3,0)
 ;;=3^285.21
 ;;^UTILITY(U,$J,358.3,19879,1,4,0)
 ;;=4^ANEMIA IN CHR KIDNEY DISEASE
 ;;^UTILITY(U,$J,358.3,19879,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,19880,0)
 ;;=280.9^^112^1193^12
 ;;^UTILITY(U,$J,358.3,19880,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19880,1,3,0)
 ;;=3^280.9
 ;;^UTILITY(U,$J,358.3,19880,1,4,0)
 ;;=4^IRON DEFIC ANEMIA NOS
 ;;^UTILITY(U,$J,358.3,19880,2)
 ;;=^276946
 ;;^UTILITY(U,$J,358.3,19881,0)
 ;;=389.9^^112^1194^7
 ;;^UTILITY(U,$J,358.3,19881,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19881,1,3,0)
 ;;=3^389.9
 ;;^UTILITY(U,$J,358.3,19881,1,4,0)
 ;;=4^HEARING LOSS
 ;;^UTILITY(U,$J,358.3,19881,2)
 ;;=^54552
 ;;^UTILITY(U,$J,358.3,19882,0)
 ;;=380.4^^112^1194^8
 ;;^UTILITY(U,$J,358.3,19882,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19882,1,3,0)
 ;;=3^380.4
 ;;^UTILITY(U,$J,358.3,19882,1,4,0)
 ;;=4^IMPACTED CERUMEN
 ;;^UTILITY(U,$J,358.3,19882,2)
 ;;=^62061
 ;;^UTILITY(U,$J,358.3,19883,0)
 ;;=382.9^^112^1194^9
 ;;^UTILITY(U,$J,358.3,19883,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19883,1,3,0)
 ;;=3^382.9
